EP3321271A4 - PROCESS FOR THE PREPARATION OF 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF - Google Patents
PROCESS FOR THE PREPARATION OF 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF Download PDFInfo
- Publication number
- EP3321271A4 EP3321271A4 EP16821437.7A EP16821437A EP3321271A4 EP 3321271 A4 EP3321271 A4 EP 3321271A4 EP 16821437 A EP16821437 A EP 16821437A EP 3321271 A4 EP3321271 A4 EP 3321271A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrrolo
- preparation
- pyrimidine derivative
- pyrimidine
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015136196 | 2015-07-07 | ||
| PCT/JP2016/070046 WO2017006968A1 (en) | 2015-07-07 | 2016-07-06 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3321271A1 EP3321271A1 (en) | 2018-05-16 |
| EP3321271A4 true EP3321271A4 (en) | 2020-12-16 |
| EP3321271B1 EP3321271B1 (en) | 2024-05-29 |
Family
ID=57685105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP16821437.7A Active EP3321271B1 (en) | 2015-07-07 | 2016-07-06 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10822354B2 (en) |
| EP (1) | EP3321271B1 (en) |
| JP (1) | JP6871856B2 (en) |
| KR (1) | KR20180025940A (en) |
| CN (1) | CN107709337B (en) |
| AU (1) | AU2016289061B2 (en) |
| BR (1) | BR112017026173A2 (en) |
| CA (1) | CA2991020A1 (en) |
| HK (1) | HK1251223A1 (en) |
| IL (1) | IL255775B (en) |
| MX (1) | MX2017016772A (en) |
| RU (1) | RU2755618C2 (en) |
| TW (1) | TWI729990B (en) |
| WO (1) | WO2017006968A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1251223A1 (en) | 2015-07-07 | 2019-01-25 | Japan Tobacco, Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| JP2020502224A (en) * | 2016-12-21 | 2020-01-23 | 日本たばこ産業株式会社 | Crystal forms of Janus kinase inhibitors |
| CN110300756B (en) | 2016-12-21 | 2024-01-02 | 日本烟草产业株式会社 | Preparation method of 7H-pyrrolo[2,3-d]pyrimidine derivatives and its synthetic intermediates |
| BR112019012267A2 (en) | 2016-12-21 | 2019-12-03 | Japan Tobacco Inc | Process for the preparation of 7h-pyrrolo [2,3-d] pyrimidine derivative and cocrystals thereof |
| KR20190105417A (en) | 2018-03-05 | 2019-09-17 | 현대자동차주식회사 | Coupling diagnostic method of breather hose |
| JP2022526713A (en) | 2019-03-21 | 2022-05-26 | オンクセオ | Dbait molecule in combination with a kinase inhibitor for the treatment of cancer |
| CN114173788A (en) * | 2019-08-07 | 2022-03-11 | 乐敦制药株式会社 | Ophthalmic composition for promoting tear secretion |
| KR20220098759A (en) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | A method of treating cancer that has acquired resistance to a kinase inhibitor |
| WO2021132598A1 (en) | 2019-12-27 | 2021-07-01 | ロート製薬株式会社 | Aqueous composition |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111606929B (en) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | Preparation method of Degatinib |
| CN111574540B (en) * | 2020-06-30 | 2023-08-29 | 云南华派医药科技有限公司 | Preparation method of Degatinib |
| JPWO2022025279A1 (en) | 2020-07-30 | 2022-02-03 | ||
| EP4176881A4 (en) | 2020-07-30 | 2024-07-31 | Rohto Pharmaceutical Co., Ltd. | AQUEOUS COMPOSITION |
| AU2024229918A1 (en) | 2023-02-28 | 2025-09-18 | Assia Chemical Industries Ltd. | Solid state forms of delgocitinib and process thereof |
| WO2024225445A1 (en) | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2335380A1 (en) * | 2008-09-24 | 2010-03-25 | Consejo Superior De Investigaciones Cientificas (Cic) | NEW QUATERNARY AMINO ACIDS DERIVED FROM AZEPANOS AND ITS APPLICATIONS. |
| US20110136778A1 (en) * | 2009-07-31 | 2011-06-09 | Japan Tobacco Inc. | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof |
| WO2012098033A1 (en) * | 2011-01-19 | 2012-07-26 | Galapagos Nv | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7230119B2 (en) | 2004-08-25 | 2007-06-12 | Biocryst Pharmaceuticals, Inc. | Process for the preparation of substituted pyrrolidine derivatives and intermediates |
| DK2078022T3 (en) | 2006-09-22 | 2012-02-13 | Janssen Pharmaceutica Nv | Spirobenzazepines used as vasopressin antagonists |
| CN103570601B (en) | 2012-07-20 | 2016-03-30 | 重庆博腾制药科技股份有限公司 | A kind of preparation method of optical active medicine intermediate |
| DK2964616T3 (en) | 2013-03-05 | 2017-08-28 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
| HK1251223A1 (en) | 2015-07-07 | 2019-01-25 | Japan Tobacco, Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| CN110300756B (en) | 2016-12-21 | 2024-01-02 | 日本烟草产业株式会社 | Preparation method of 7H-pyrrolo[2,3-d]pyrimidine derivatives and its synthetic intermediates |
-
2016
- 2016-07-06 HK HK18110560.9A patent/HK1251223A1/en unknown
- 2016-07-06 JP JP2017527480A patent/JP6871856B2/en active Active
- 2016-07-06 US US15/741,926 patent/US10822354B2/en active Active
- 2016-07-06 EP EP16821437.7A patent/EP3321271B1/en active Active
- 2016-07-06 AU AU2016289061A patent/AU2016289061B2/en not_active Ceased
- 2016-07-06 MX MX2017016772A patent/MX2017016772A/en unknown
- 2016-07-06 KR KR1020187003308A patent/KR20180025940A/en not_active Ceased
- 2016-07-06 CN CN201680040056.7A patent/CN107709337B/en active Active
- 2016-07-06 CA CA2991020A patent/CA2991020A1/en not_active Abandoned
- 2016-07-06 TW TW105121354A patent/TWI729990B/en not_active IP Right Cessation
- 2016-07-06 BR BR112017026173-1A patent/BR112017026173A2/en not_active IP Right Cessation
- 2016-07-06 WO PCT/JP2016/070046 patent/WO2017006968A1/en not_active Ceased
- 2016-07-06 RU RU2018104347A patent/RU2755618C2/en active
-
2017
- 2017-11-20 IL IL255775A patent/IL255775B/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2335380A1 (en) * | 2008-09-24 | 2010-03-25 | Consejo Superior De Investigaciones Cientificas (Cic) | NEW QUATERNARY AMINO ACIDS DERIVED FROM AZEPANOS AND ITS APPLICATIONS. |
| US20110136778A1 (en) * | 2009-07-31 | 2011-06-09 | Japan Tobacco Inc. | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof |
| WO2012098033A1 (en) * | 2011-01-19 | 2012-07-26 | Galapagos Nv | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases |
Non-Patent Citations (4)
| Title |
|---|
| DIEGO NÚÑEZ-VILLANUEVA ET AL: "Divergent, stereoselective access to heterocyclic [alpha],[alpha]-quaternary- and [beta] 2,3,3 -amino acid derivatives from a N-Pmp-protected Orn-derived [beta]-lactam", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 13, no. 18, 1 January 2015 (2015-01-01), pages 5195 - 5201, XP055742125, ISSN: 1477-0520, DOI: 10.1039/C5OB00429B * |
| DIEGO NUNEZ-VILLANUEVA ET AL: "Quaternary a, alpha-2-Oxoazepane a-Amino Acids: Synthesis from Ornithine-Derived beta-Lactams and Incorporation into Model Dipeptides", JOURNAL OF ORGANIC CHEMISTRY, vol. 76, no. 16, 30 June 2011 (2011-06-30), pages 6592 - 6603, XP055605874, ISSN: 0022-3263, DOI: 10.1021/jo200894d.Source: * |
| PAULA PREZ-FAGINAS ET AL: "Synthesis and SAR studies on azetidine-containing dipeptides as HCMV inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 19, no. 3, 23 December 2010 (2010-12-23), pages 1155 - 1161, XP028133980, ISSN: 0968-0896, [retrieved on 20101230], DOI: 10.1016/J.BMC.2010.12.052 * |
| See also references of WO2017006968A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10822354B2 (en) | 2020-11-03 |
| JPWO2017006968A1 (en) | 2018-04-19 |
| TWI729990B (en) | 2021-06-11 |
| WO2017006968A1 (en) | 2017-01-12 |
| HK1251223A1 (en) | 2019-01-25 |
| CA2991020A1 (en) | 2017-01-12 |
| JP6871856B2 (en) | 2021-05-19 |
| AU2016289061A1 (en) | 2017-12-21 |
| CN107709337B (en) | 2021-11-16 |
| CN107709337A (en) | 2018-02-16 |
| KR20180025940A (en) | 2018-03-09 |
| AU2016289061B2 (en) | 2020-07-09 |
| BR112017026173A2 (en) | 2018-08-14 |
| MX2017016772A (en) | 2018-05-14 |
| IL255775B (en) | 2021-03-25 |
| RU2018104347A3 (en) | 2019-12-23 |
| RU2755618C2 (en) | 2021-09-17 |
| US20190062346A1 (en) | 2019-02-28 |
| EP3321271A1 (en) | 2018-05-16 |
| TW201708231A (en) | 2017-03-01 |
| RU2018104347A (en) | 2019-08-08 |
| EP3321271B1 (en) | 2024-05-29 |
| IL255775A (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3321271A4 (en) | PROCESS FOR THE PREPARATION OF 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | |
| EP3560932A4 (en) | PROCESS FOR THE PREPARATION OF 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATE THEREOF | |
| EP3582784A4 (en) | PROCESS FOR THE PREPARATION OF BENZODIAZEPINE DERIVATIVES | |
| IL266170A (en) | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | |
| EP3532560A4 (en) | FUNCTIONAL GRINDING ARTICLES, GRINDING ARTICLES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3464175A4 (en) | PROCESS FOR THE PREPARATION OF BORONITRIDAGGLOMERATES | |
| EP3324759C0 (en) | METHOD FOR THE MANUFACTURE OF TOBACCO PRODUCTS | |
| HUE057549T2 (en) | Imidazo [1,2-a] pyrimidine derivatives, process for their preparation and their use | |
| EP2819978A4 (en) | PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES | |
| HUE050320T2 (en) | PDE1 inhibitor 1,5-dihydro-4H-pyrazolo [3-4-d] pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo [3-4-d] pyridin-4-ones | |
| EP3560931A4 (en) | METHOD FOR PRODUCING A 7H-PYRROLO [2,3-D] PYRIMIDINE DERIVATIVE AND CO-CRYSTAL OF THE SAME DERIVATIVE | |
| EP3373910C0 (en) | ECHINOMYCIN FORMULATIONS, METHOD OF PREPARATION AND METHOD OF USE THEREOF | |
| EP3642181A4 (en) | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | |
| EP3455312A4 (en) | AQUEOUS COATING COMPOSITION AND METHOD FOR PRODUCING THE SAME | |
| EP3612637A4 (en) | PROCESS FOR THE PRODUCTION OF DUAL FUNCTION PROTEINS AND THEIR DERIVATIVES | |
| EP3582773A4 (en) | PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF | |
| IL287119A (en) | Bryostatin compounds and methods of preparing the same | |
| EP3431520C0 (en) | METHOD FOR THE PREPARATION OF OXYMETHYLENE COPOLYMER | |
| EP3538524C0 (en) | PROCESS FOR THE PREPARATION OF UMECLIDINIUM BROMIDE | |
| EP2931906A4 (en) | PROCESS FOR THE PREPARATION OF FURFURAL | |
| DK3362453T3 (en) | CYCLIC ETHERERIVATIVES OF PYRAZOLO [1,5-A] PYRIMIDINE-3-CARBOXYAMIDE | |
| IL262405A (en) | Methods for the preparation of obeticholic acid and derivatives thereof | |
| EP3687940A4 (en) | SELF-ASSEMBLY PROCESS FOR THE MANUFACTURE OF IGEL-SHAPED PARTICLES | |
| EP3546439A4 (en) | PROCESS FOR THE PREPARATION OF (Z) -1-CHLORO-2,3,3-TRIFLUORO-1-PROPENE | |
| EP3597593A4 (en) | PROCESS FOR THE PREPARATION OF PHOSPHORUS PENTAFLUORIDE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20180207 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1251223 Country of ref document: HK |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 205/04 20060101ALI20190222BHEP Ipc: A61K 31/519 20060101ALI20190222BHEP Ipc: C07D 519/00 20060101AFI20190222BHEP Ipc: C07D 487/10 20060101ALI20190222BHEP Ipc: A61P 43/00 20060101ALI20190222BHEP Ipc: C07B 61/00 20060101ALI20190222BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JAPAN TOBACCO INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20201112 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07B 61/00 20060101ALI20201106BHEP Ipc: A61P 43/00 20060101ALI20201106BHEP Ipc: C07D 487/10 20060101ALI20201106BHEP Ipc: A61K 31/519 20060101ALI20201106BHEP Ipc: C07D 519/00 20060101AFI20201106BHEP Ipc: C07D 205/04 20060101ALI20201106BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20221020 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240108 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20240419 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016087756 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240929 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240830 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1690557 Country of ref document: AT Kind code of ref document: T Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240829 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240929 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240830 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240829 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016087756 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240706 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240706 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240731 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240731 |
|
| 26N | No opposition filed |
Effective date: 20250303 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20240731 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250515 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250508 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240706 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240529 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240529 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250514 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20160706 |